Autism and Other Psychiatric Comorbidity in Neurofibromatosis Type 1: Evidence from a Population-based Study
Overview
Authors
Affiliations
Aim: To investigate psychopathology in children with neurofibromatosis type 1 (NF1), particularly the prevalence of autism spectrum disorder (ASD) and attention-deficit-hyperactivity disorder (ADHD) symptomatology, using a population-based sampling approach.
Method: Standard questionnaire screen reports were analysed for ASD (Social Responsiveness Scale, SRS), ADHD (Conners' Parent Rating Scale- Revised, CPRS-R), and other psychiatric morbidity (Strengths and Difficulties Questionnaire, SDQ) from parents and teachers of children aged from 4 to 16 years (112 females, 95 males) on the UK North West Regional Genetic Service register for NF1.
Results: Parental response rate was 52.7% (109/207 children; 59 females, 50 males, mean age 9 y 11 mo, SD 3 y 3 mo). The SRS showed that in 29.4% (32/109) of children, autism was in the severe, clinical range (T-score>75) and in 26.6% (29/109) in the mild to moderate range (T-score 60-75). CPRS-R scores showed that in 53.8% (57/106) of children autism was in the clinical ADHD range (ADHD index T-score>65). Based on their scores on the SDQ total difficulties scale, 41.5% (44/106) of children were in the abnormal range and 14.2% (15/106) were in the borderline range. Twenty-five per cent (26/104) of children met criteria for both clinical autism and ADHD.
Interpretation: This representative population-based sample of children with NF1 indicates a high prevalence of ASD symptoms associated with NF1 as well as substantial co-occurrence with ADHD symptoms. The findings clarify the psychopathology of NF1 and show the disorder as a potentially important single-gene cause for autism symptoms.
Begum-Ali J, Mason L, Charman T, Johnson M, Green J, Garg S J Neurodev Disord. 2025; 17(1):12.
PMID: 40087579 DOI: 10.1186/s11689-025-09599-4.
Developmental trajectories in infants and pre-school children with Neurofibromatosis 1.
Slevin H, Kehinde F, Begum-Ali J, Ellis C, Burkitt-Wright E, Green J Mol Autism. 2024; 15(1):45.
PMID: 39407332 PMC: 11481376. DOI: 10.1186/s13229-024-00621-5.
Siqueiros-Sanchez M, Serur Y, McGhee C, Smith T, Green T Biol Psychiatry. 2024; 97(5):461-498.
PMID: 39366539 PMC: 11805629. DOI: 10.1016/j.biopsych.2024.09.019.
Siqueiros-Sanchez M, Dai E, McGhee C, McNab J, Raman M, Green T Brain Commun. 2024; 6(4):fcae274.
PMID: 39210910 PMC: 11358645. DOI: 10.1093/braincomms/fcae274.
Nadermohammadi Moghadam M, Bakhshi P, Azarkollah A, Moulai B, Molavi P Iran J Psychiatry. 2024; 19(3):254-264.
PMID: 39055521 PMC: 11267122. DOI: 10.18502/ijps.v19i3.15802.